Current Research into Cures for Type-1 Diabetes: News from ADA 2018

Friday, June 29, 2018

News from ADA 2018

The American Diabetes Association's Scientific Sessions for 2018 (called ADA2018 with hastag #2018ADA) just ended. I was not there, but did monitor twitter and other social media to get a feel for what was going on. As in previous years, it was about 90% type-2 and about 90% treatments (not cures), and of the remaining type-1/cure research, only a little was human trials of the type covered in this blog.

So anyway, here is a huge list of links (mostly links to tweets) which I found interesting for one reason or other. I've tried to categorize them, and in a few cases, after the link, I've added a sentence or two about why I found them interesting.

Summary web sites:
https://beyondtype1.org/breaking-news-from-ada2018/
https://www.healio.com/endocrinology/meeting-news/ada-conference
https://www.diabetesdaily.com/blog/clinical-trials-in-type-1-diabetes-ada-2018-580153/
https://www.medscape.com/viewcollection/34397
http://www.mdmag.com/conference-coverage/ada-2018

Cure Related
ATG/GCSF:
https://twitter.com/BeyondType1/status/1011252403079745536
https://twitter.com/Judithendo/status/1011240300742893568
Meta-Dopa, which I need to blog about:
https://twitter.com/Judithendo/status/1011291591875743744
Encapsulation for beta cells (animals, I think):
https://twitter.com/Cristob_Morales/status/1011230794831089667

Smart Insulin:
https://twitter.com/mbotana/status/1010599897987473410
https://pubs.acs.org/doi/abs/10.1021/acsnano.7b08152

ViaCyte:
https://twitter.com/ViaCyte/status/1010508277766082560
https://twitter.com/ViaCyte/status/1010493177273442304
https://viacyte.com/archives/press-releases/two-year-data-from-viacytes-step-one-clinical-trial-presented-at-ada-2018

Artificial Pancreas:
There were lots more, but these really called out to me.
https://twitter.com/danamlewis/status/1010527143938416641
https://openaps.org/2018/06/23/detecting-insulin-sensitivity-changes-for-individuals-with-type-1-diabetes-with-autosensitivity-from-openaps-poster-presented-at-american-diabetes-association-scientific-sessions-2018ada/
https://www.healio.com/endocrinology/diabetes/news/online/%7B904dc31d-db81-47e7-9a82-c183e2aca8c4%7D/6-month-implantable-cgm-safe-accurate-in-teens-adults

General Interest:
https://twitter.com/em_saidwhat/status/1010513691056451584
Pregnancy: https://twitter.com/RenzaS/status/1010494620512473088
Average A1c by age: https://twitter.com/RenzaS/status/1010476210088886272
Vit D: https://twitter.com/cristinatejerap/status/1010589989678305280
T2D delays T1D? https://twitter.com/cristinatejerap/status/1010604154186817537
Mice vs. Humans: https://twitter.com/Cell_Onion/status/1010543301580279808
Gut not important? https://twitter.com/DrKirstieBell/status/1010618697440989184
Patch Pump: https://www.healio.com/endocrinology/diabetes/news/online/%7B8540d455-ebc8-4e78-a1dc-f4440bc9cf18%7D/investigational-patch-pump-artificial-pancreas-safe-effective-under-free-living-conditions
Half Units Matter: https://twitter.com/Diabetes_Videos/status/1011391416889696256
Adjunct Therapy: https://www.boehringer-ingelheim.com/press-release/type-1-diabetes?
Bariatric Surgery T1D: https://twitter.com/Ali_Aminian_MD/status/1011647953667272704
SGLT:
https://twitter.com/MarkHarmel/status/1011646768776392705
https://twitter.com/AmDiabetesAssn/status/1010860753589587968
https://www.healio.com/news/online/%7B943b8bde-157a-4d87-ae3c-5f1f1d2fe2d5%7D/dual-sglt-inhibitor-boosts-insulin-efficacy-in-type-1-diabetes

New Patch Pump: https://twitter.com/SanofiDCV/status/1011617549174353920

Type-2:
Lots of comorbid conditions: https://twitter.com/AstraZenecaUS/status/1010526644656799744

Transplants:
https://twitter.com/drpratikc/status/1011353557013073920
An attempt at a head-to-head comparison of islet transplants vs. Artificial Pancreas results. Interesting!

The other form of bihormonal AP:
https://twitter.com/EndocrineToday/status/1011330691009658880
Most bihormonal AP research uses insulin and glucagon, but this one uses insulin and pramlintide.

Faustman:
News: https://www.healthline.com/diabetesmine/denise-faustman-research-pushback-ada-jdrf?platform=hootsuite
Discussion: https://twitter.com/Drbeth_/status/1010431411671748608
Poster and Discussion: https://twitter.com/HangryPancreas/status/1011294476260831233
ADA and JDCA joint letter (later supported by the Berrie Center):
https://twitter.com/keddy_moise/status/1011420460612030464
https://twitter.com/DiabetesMine/status/1011400346441220096
https://twitter.com/JDRF/status/1011399303665995776
https://twitter.com/nbdiabetes/status/1011640607259930625
These two guys (and many others) report dropping A1c, but no one calls them a cure:
https://twitter.com/snp_io/status/1010616966523088896
https://twitter.com/Fallabel/status/1011280750967246848

Interesting to me:
Open Data Tools for Software Nerds: https://twitter.com/stales/status/1010599135576231936
I found the next tweet interesting because Cure was in title, but treatment in contents. To me that shows a problem with "cure" research. Much of it is not really aimed at a cure:
https://twitter.com/DanielJDrucker/status/1010870015183278080
TEDDY:
https://twitter.com/cristinatejerap/status/1010586167102922752
https://twitter.com/ERobertson02/status/1010614817244286976
https://www.healio.com/endocrinology/diabetes/news/online/%7B78982aaa-a6f8-4b1f-a74b-04e3bc6e760a%7D/insights-from-teddy-study-provide-clues-to-islet-autoimmunity-in-children

Low Carb:
https://twitter.com/DikemanDave/status/1011393166849728512
https://twitter.com/JPMcCarter/status/1011328194115522560
https://www.diabetesdaily.com/blog/very-low-carbohydrate-diets-for-diabetes-ada-2018-580309/?utm_campaign=coschedule&utm_source=twitter&utm_medium=diabetesdaily&utm_content=Very%20Low%20Carbohydrate%20Diets%20for%20Diabetes%20(ADA%202018)
https://twitter.com/JPMcCarter/status/1011697843260837888
https://www.linkedin.com/feed/update/urn:li:activity:6417463469972430848/

Atkinson honored (nPOD and much more):
https://twitter.com/_HealthMyself/status/1011262077191716864
https://twitter.com/HIRN_CC/status/1011255219202633728

The "Most Obvious Research Conclusion Award"
https://twitter.com/DrKirstieBell/status/1010881942974291968

Joshua Levy
http://cureresearch4type1diabetes.blogspot.com
publicjoshualevy at gmail dot com
All the views expressed here are those of Joshua Levy, and nothing here is official JDRF, JDCA, or Bigfoot Biomedical news, views, policies or opinions. In my day job, I work in software for Bigfoot Biomedical. My daughter has type-1 diabetes and participates in clinical trials, which might be discussed here. My blog contains a more complete non-conflict of interest statement. Thanks to everyone who helps with the blog.

2 comments:

Unknown said...: Dear Joshua,

I read your blog since 2012, and I can say I know your articles by far. Even if you are not a researcher or a doctor, you were impartial and you made a concise summary. But since you joint to the JDRF camp, I wonder what happened to you. I'm referring to the Faustman study, of course. You published only the counterattacks. You know too well and you have written it many times that the insulin market is over 20 billion at the moment.
I also think you remember how many times you've written about medicines that were used in studies, and with the publication of more than encouraging reports, the manufacturer withdrew that drug from the market.
I would like to see you writing an article about "Pancreate", why has not there been any news from 2009-2010, when Sanofi bought it from CureDM.com for 350+ million dollars? Not even one article since then.
I would like to see you writing an article about what will happen if tomorrow a cure will suddenly appear, what will be the impact on Big Pharma? Of course, you know this will not happen, you also said this in one of your articles, cause this is closely monitored and regulated.
The good thing is that the BCG can not be removed from the market, but the bad thing is that hyenas can stop any study like this, anytime.
I am very sorry that the only publication that treated each topic, any news with so much impartiality disappeared.
Now I am asking also if you will you post my comment.
Thanks; July 4, 2018 at 11:48 PM
Best Link Builder said...: This comment has been removed by a blog administrator.; July 8, 2018 at 3:00 AM

My Non-Conflict of Interest Statement

For the first 10 years of running this blog, I did not work for a company doing medical research. In 2018, I started working for Bigfoot Biomedical, which is developing an "automated insulin dosing/delivery solution" (what many call an Artificial Pancreas).
I blog on research aimed at curing type-1 diabetes, and I view Bigfoot Biomedical's work as treating type-1 diabetes (not a cure at all). Therefore, I don't view this work as conflicting with my blogging. However, if you consider the kind of automated insulin dosing/delivery solution that Bigfoot is developing to be an actual cure for type-1, then this would conflict with my blogging. I think they are quite different.
I don't get paid in any way by any company working on a cure for type-1 diabetes; I never have. And that includes free samples, free travel, or free anything. I do sometimes participate in market research studies or focus groups, and they sometimes pay.
None of the hours that I have put into my blog, or the posts that I make to any web site, has ever been paid for. (Except for some very nice and heart felt thank-you emails, and those are worth more than money.)
My daughter has type-1 diabetes and participates in clinical trials. I sometimes report on trials that she participates in, but I do not reveal her participation because I consider her medical history to be private.
I sometimes "beta test" new software or devices involved in type-1 diabetes. When I'm blogging about something where I have been given special access, I say so.
In the past I have volunteered with JDRF and The NIIB Project. I currently am a fellow with JDCA. The JDRF and NIIB work was completely unpaid. JDCA has given me equipment that I use to help my blogging, and on one occasion paid for specific consulting work.